Off-Label Risks: Compliance Matters Now More Than Ever
MP3•Episodio en casa
Manage episode 421766467 series 3506216
Contenido proporcionado por Darshan Kulkarni. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Darshan Kulkarni o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
We shed light on the complexities surrounding off-label promotion and reimbursement in the pharmaceutical industry.
We discuss the following:
- What does off-label mean from a reimbursement standpoint?
- Lessons from the US v. Eli Lilly 2009 case
- How do recent court decisions impact off-label promotion? United States v. Caronia and US v. Facteau
- How are weight loss drugs, initially approved for treating diabetes, reimbursed within Medicare and Medicaid?
- How are compounded drugs reimbursed?
- Could a company be held accountable for off-label use of a drug due to
- compounded products?
- Are weight loss drugs exempted from reimbursement?
84 episodios